press release

Jan. 20, 2022, 7:09 a.m. EST

4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004

LEEDS, England, (BUSINESS WIRE) -- 4D pharma plc (aim:DDDD) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that it will host a virtual Key Opinion Leader (KOL) event to review previously disclosed positive topline results from Part A of its Phase I/II trial of MRx-4DP0004 for the treatment of asthma and to discuss the asthma treatment landscape. The event will take place on Thursday, January 27, 2022, from 8:00 a.m. ET (1:00 p.m. GMT).

The event will feature presentations from 4D pharma management and KOL, Professor Chris Brightling, National Institute for Health Research (NIHR) Senior Investigator and Clinical Professor in Respiratory Medicine, Department of Respiratory Sciences, University of Leicester, UK, and Principle Investigator of the MRx-4DP0004 Phase I/II trial.

A live webcast of the event will be available on the Reports and Presentations section of the 4D Pharma website at . A replay of the webcast and accompanying slides will be available on the 4D pharma website following the event.

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism. 4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to

View source version on

SOURCE: 4D pharma plc

Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130
Investor Relations Singer Capital Markets - Nominated Adviser and Joint Broker +44 (0)20 7496 3000
Philip Davies / James Fischer (Corporate Finance)
Tom Salvesen (Corporate Broking) Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson Stern Investor Relations
Julie Seidel +1-212-362-1200 Image Box Communications
Neil Hunter / Michelle Boxall +44 (0)20 8943 4685 6 Degrees
Lynne Dardanell +1-336-202-9689


Is there a problem with this press release? Contact the source provider Comtex at You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2022


Partner Center

Link to MarketWatch's Slice.